Lexicon Pharmaceuticals, Inc. has obtained exclusive research, development and commercialization rights to LX9211 (BMS-986176), a drug candidate for neuropathic pain that was jointly developed by Lexicon and Bristol-Myers Squibb as part of their neuroscience drug discovery alliance. Additional small molecule compounds acting through the same target as LX9211 are also included in the exclusive agreement. LX9211 is currently completing IND-enabling studies, with Phase I trials expected to begin in...